ArriVent says Phase 3 trial of firmonertinib in EGFR exon 20 lung cancer missed primary PFS endpoint; shares fall 58%

ArriVent announced that its Phase 3 trial of firmonertinib in EGFR exon 20 lung cancer missed the primary progression-free survival endpoint. Shares fell 58% on the news.

Detected & updated continuously · Source: Nebula